A RECOMBINANT FUSION PROTEIN THAT MIMICS THE INFLAMMATORY BIOMARKER CALPROTECTIN AS A TOOL TO HARMONIZE MRP-8/MRP-14 IMMUNOASSAYS

Alexander Ohmann¹, Dmitrii Guschin¹, Peter Spies², Dominik Meinel² and Christian-B. Gerhold^{1,*}

*correspondence to: cbg@buhlmannlabs.ch; +41 61 487 12 52


¹ BÜHLMANN Laboratories AG - 4124 Schönenbuch, Switzerland
² Fachhochschule Nordwestschweiz - 4132 Muttenz, Switzerland


ÖBÜHLMANN

7 Fachhochschule Nordwestschwei

Background and aims

Calprotectin is a granulocyte-derived alarmin protein complex of Mrp-8 and Mrp-14 that indicates the inflammatory state of a patient. Fecal calprotectin is already established as the gold standard for diagnostics and monitoring of inflammatory bowel diseases and blood-circulating or serum calprotectin is emerging as an important biomarker for i.e. rheumatoid arthritis. However, standardization of calprotectin assays differs significantly among providers leading to varying clinical cut-offs. A suspected reason is that calprotectin's different oligomeric states can generate different quantitative results. The aim of this work was to produce a pure and stable calprotectin surrogate that fully mimics the manifold characteristics of this inflammatory biomarker.







P1550


Methods


The oligomeric state of a recombinant fusion protein between Mrp-8 and Mrp-14 that expressed solubly in *E. coli* was assessed by size-exclusion chromatography. Direct comparison to native calprotectin regarding antibody affinities were measured using BLI (bio-layer interferometry) and SPR (surface plasmon resonance) and its use as calibrator material in various monoclonal and polyclonal immunoassay formats was tested. Moreover, growth curves of *S. aureus* were recorded in the presence of native and recombinant calprotectin.






Concentration dependent measurements of recombinant calprotectin spiked incubation buffer shows linear behavior in the BÜHLMANN fCAL® turbo assay (A) as well as in the fCAL® ELISA (B). (C) Measurement of RCAL with both a polyclonal antibody-based turbidimetric assay as well as a monoclonal antibody-based ELISA shows comparable data to 23 patient samples. (D) Turbidimetric measurements of 23 patient samples based on calibration curves derived from recombinant or native calprotectin give rise to virtually identical values.







Size exclusion

mAu

290

240

190

140

90

analysis of RCAL

mau RCAL wt

mau RCAL N69A E78A

mAU RCAL N69A

MAU RCAL E78A

An intrinsic property of calprotectin is tetramerization in presence of Ca^{2+} ions. The recombinant protein elutes at higher SEC volumes in presence of 2 mM $CaCl_2$ indicating oligomerization. Mutations of the Ca^{2+} binding sites impair oligomerization in the case of S100A9 E78A, but not N69A mutations. The recombinant fusion protein therefore mimics native

calprotectin with respect to oligomerization.

Accelerated stability measurements at various temperatures (50°C, 45°C, 37°C and 28°C) give rise to stability estimates of more than three years for the dimer and more than seven years for the tetramer at 8°C.

Results

The fusion protein was purified as a calprotectin dimer mimic that oligomerizes in the presence of calcium ions. Affinities to monoclonal and polyclonal calprotectin antibodies were very comparable to native calprotectin. Spiking of different concentrations of recombinant calprotectin showed linear correlations in ELISA and turbidimetric assays. A perfect correlation (slope=1.009; R²=0.999) was shown when measuring 23 human serum samples based on native and recombinant calprotectin calibrators with a turbidimetric assay. Both, recombinant and native calprotectin significantly hampered *S. aureus* growth most likely due to metal sequestration of the calprotectin tetramer.

Conclusions

The recombinant protein can be purified in large quantities in defined oligomeric states and shows immunological and biophysical properties identical to native calprotectin. Recombinant calprotectin thus presents a promising tool to overcome the prevalent fecal calprotectin standardization problem and may prevent future standardization discrepancies for serum calprotectin.